Patents by Inventor Arejas Uzgiris
Arejas Uzgiris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210214810Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.Type: ApplicationFiled: March 17, 2021Publication date: July 15, 2021Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Arejas Uzgiris, Sunil Pandit, Lance Palmer
-
Patent number: 10982294Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.Type: GrantFiled: December 1, 2016Date of Patent: April 20, 2021Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Arejas Uzgiris, Sunil Pandit, Lance Palmer
-
Patent number: 10851428Abstract: The present invention is based in part on the present inventors' appreciation that certain sequences within an HIV genome are more likely to successfully detect HIV across a breadth of HIV variants. The ability to detect and/or quantify the presence and/or load of HIV in a subject is important to, among other things, the diagnosis and treatment of infected individuals. The present invention is based, in part, on the discovery of oligonucleotide reagents that detectably amplify sequences from a greater breadth of HIV samples than certain prior reagents and/or that generate amplicons from HIV genomes from which certain prior reagents would not have generated amplicons. Oligonucleotide reagents as described herein provide unexpected benefits in the detection and/or quantification of the presence and/or load of HIV in a subject, and thereby in the diagnosis and treatment of HIV.Type: GrantFiled: September 16, 2016Date of Patent: December 1, 2020Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Sunil Pandit, Arejas Uzgiris, Lance Palmer
-
Publication number: 20180245166Abstract: The present invention is based in part on the present inventors' appreciation that certain sequences within an HIV genome are more likely to successfully detect HIV across a breadth of HIV variants. The ability to detect and/or quantify the presence and/or load of HIV in a subject is important to, among other things, the diagnosis and treatment of infected individuals. The present invention is based, in part, on the discovery of oligonucleotide reagents that detectably amplify sequences from a greater breadth of HIV samples than certain prior reagents and/or that generate amplicons from HIV genomes from which certain prior reagents would not have generated amplicons. Oligonucleotide reagents as described herein provide unexpected benefits in the detection and/or quantification of the presence and/or load of HIV in a subject, and thereby in the diagnosis and treatment of HIV.Type: ApplicationFiled: September 16, 2016Publication date: August 30, 2018Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Sunil Pandit, Arejas Uzgiris, Lance Palmer
-
Publication number: 20170137901Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.Type: ApplicationFiled: December 1, 2016Publication date: May 18, 2017Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Arejas Uzgiris, Sunil Pandit, Lance Palmer
-
Patent number: 9528163Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.Type: GrantFiled: June 20, 2012Date of Patent: December 27, 2016Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Arejas Uzgiris, Sunil Pandit, Lance Palmer
-
Publication number: 20150299814Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HIV, in particular regions that encode the V3 region of the env glycoprotein. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of the V3 region of the env glycoprotein. The oligonucleotide sequences are also provided assembled as kits that can be used to detect or sequence the V3 region of the env glycoprotein. Control nucleic acids for use in methods and kits of the present disclosure are also provided.Type: ApplicationFiled: October 10, 2013Publication date: October 22, 2015Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Arejas UZGIRIS, Sunil PANDIT, Lance PALMER
-
Patent number: 8940486Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: GrantFiled: January 4, 2011Date of Patent: January 27, 2015Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Jill Detmer, Arejas Uzgiris, Andy Ying
-
Publication number: 20140134605Abstract: The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.Type: ApplicationFiled: June 20, 2012Publication date: May 15, 2014Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Arejas Uzgiris, Sunil Pandit, Lance Palmer
-
Publication number: 20120288863Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.Type: ApplicationFiled: January 4, 2011Publication date: November 15, 2012Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Jill Detmer, Arejas Uzgiris, Andy Ying
-
Patent number: 8119349Abstract: The present invention is directed to a method for detecting the presence or absence of a mutation of interest in the nucleic acid of a pathogen, wherein the mutation of interest is located adjacent to a length polymorphism defining multiple quasispecies of the pathogen.Type: GrantFiled: October 12, 2010Date of Patent: February 21, 2012Assignee: Siemens Healthcare Diagnostics, Inc.Inventors: Arejas Uzgiris, Sharon Kemp
-
Publication number: 20110020791Abstract: The present invention is directed to a method for detecting the presence or absence of a mutation of interest in the nucleic acid of a pathogen, wherein the mutation of interest is located adjacent to a length polymorphism defining multiple quasispecies of the pathogen.Type: ApplicationFiled: October 12, 2010Publication date: January 27, 2011Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.Inventors: Arejas Uzgiris, Sharon Kemp
-
Patent number: 7847087Abstract: Primer sequences and a method of using such sequences for the genotyping of HIV-1-containing samples, particularly those which have failed genotyping analysis are provided using primer sequences designed for analysis of Group B subtype of the Group M type virus. For example, a combination of primers, including at least one species of forward primer and at least one species of reverse primer where the forward primer(s) can be represented by the degenerate sequence: RARRARGGGCTGYTGGARATGTS (Seq. ID No. 9) and the reverse primer(s) can be represented by the degenerate sequence: BCHTYACYTTRATCCCSGVRTARATYTGACT (Seq. ID No.: 10) or BCHTYACYTTRATCCCSGVRTARATYTGAC (Seq. ID No. 12) are suitably employed. The selected primers, one or more from each group, can be used as reverse transcription, amplification and sequencing primers and are suitably packaged in a genotyping kit.Type: GrantFiled: March 5, 2002Date of Patent: December 7, 2010Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Tzong-Jyh Huong, Robert M. Lloyd, Jr., Arejas Uzgiris
-
Publication number: 20080233566Abstract: The present invention is directed to a method for detecting the presence or absence of a mutation of interest in the nucleic acid of a pathogen, wherein the mutation of interest is located adjacent to a length polymorphism defining multiple quasispecies of the pathogen.Type: ApplicationFiled: August 19, 2005Publication date: September 25, 2008Inventors: Arejas Uzgiris, Sharon Kemp
-
Publication number: 20050084854Abstract: Primer sequences and a method of using such sequences for the genotyping of HIV-1-containing samples, particularly those which have failed genotyping analysis are provided using primer sequences designed for analysis of Group B subtype of the Group M type virus. For example, a combination of primers, including at least one species of forward primer and at least one species of reverse primer where the forward primer(s) can be represented by the degenerate sequence: RARRARGGGCTGYTGGARATGTS (Seq. ID No. 9) and the reverse primer(s) can be represented by the degenerate sequence: BCHTYACYTTRATCCCSGVRTARATYTGACT (Seq. ID No.: 10) or BCHTYACYTTRATCCCSGVRTARATYTGAC (Seq. ID No. 12) are suitably employed. The selected primers, one or more from each group, can be used as reverse transcription, amplification and sequencing primers and are suitably packaged in a genotyping kit.Type: ApplicationFiled: March 5, 2002Publication date: April 21, 2005Inventors: Tzong-Jyh Huong, Robert Lloyd Jr., Arejas Uzgiris